Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

• the present application relates to a new pharmaceutical composition intended for the oral route containing, as active principle, clometacin or 3- (4-chlorobenzoyl) 6-metho ⁇ y 2-methylindolo 1-acetic acid, as well as its preparation process.
• clometacin or 3- (4-chlorobenzoyl) 6-metho ⁇ y 2-methylindolo 1-acetic acid, as well as its preparation process.
• the Applicant has set itself the objective of preparing an oral pharmaceutical form of clometacin endowed with great precocity of action, great bioavailability, and good regularity of absorption of one patient to another.
• the Applicant has also prepared granules by extrusion; it prepared such granules without adjuvant, then with basic adjuvants: triethanolamine and potassium acid phosphate. No improvement in the rate of resorption or bioavailability of clometacin was also observed with these forms.
• the Applicant then prepared by extrusion, granules containing an alkaline carbonate as a basic adjuvant, and it found quite surprisingly that these granules were shown to be endowed with rapidity of action and overall bioavailability very greatly increased.
• clometacin consists of granules obtained by extrusion, containing from 50 to 70% of clometacin, and from 5 to 20% of an alkali carbonate, and preferably 58 to 60% of clometacin and 9.5 to 13% of an alkali carbonate, as well as an anhydrous granulation excipient by the wet route.
• the alkali carbonate can for example be sodium carbonate or preferably potassium carbonate.
• Clometacin is a product with analgesic properties described for example in BSM No. 7337 M by Roussel-Uclaf.
• the preparation of clometacin granules requires a granulation excipient in order to form solid aggregates of active ingredient particles.
• the granulation excipient preferably consists of one or more adjuvants chosen from the groups of diluents, binders, disintegrants and lubricants.
• the diluents serve to increase the volume of the mass of powder to be worked; they can also increase the malleability of the mass and have other secondary properties, such as serving as a binder.
• Suitable diluents include for example starch and its derivatives, lactose, mannitol, and preferably celluloses such as microcrystalline celluloses had Avicel ® PH101.
• Microcrystalline cellulose for example, also improves the malleability of the powder mixture. They can be present in proportions ranging from 5 to 40% and preferably around 20%.
• the binders allow the powder particles to agglomerate together.
• Mention may for example be made of cellulose derivatives such as methyl cellulose, starch and its derivatives, and preferably polyoxyethylene glycols of low or medium molecular weight (less than or equal to 8000), in particular PEG 6000.
• PEG 6000 for example, plays both a binder and lubricant role.
• the binders can be present in proportions ranging from 1 to 10% and preferably about 5%.
• the disintegrants allow or improve the disintegration of the granules when they are ingested.
• These are, for example, water-soluble products chosen from diluents such as sucrose or lactose, or else products capable of swelling in an aqueous medium, such as starch or its derivatives, or preferably silica powder or microcriisstalline cellulose.
• diluents such as sucrose or lactose
• aqueous medium such as starch or its derivatives, or preferably silica powder or microcriisstalline cellulose.
• these products have the essential function of disintegrating, they can be used in proportions of less than 3%, preferably about 1%; when a disintegrant fulfills this function, and also fulfills the function of diluent, as microcrystalline cellulose can do, for example, it can be present in proportions ranging up to 40%, but preferably 10 to 25%.
• Lubricants improve the malleability of the working mass and allow good homogeneity of the powder mixture. Mention may be made, for example, of talc, stearates such as that of magnesium, glycerol esters such as precirol (palmito glycerol stearate), or preferably a polyoxyethylene glycol of medium or high molecular weight (greater than or equal to 6000), or hydroxypropylmethyl cellulose These products may be present in proportions of less than 10%, and preferably of approximately 5%. Their choice is important for the yield of granulation by extrusion.
• the granulation of the products according to the invention is conventionally done by dry mixing of the adjuvants constituting the excipient, with clometacin and potassium carbonate, wetting the mixture using an anhydrous solvent such as methylene chloride, or preferably a low molecular weight alkan such as isopropanol, methanol and in particular ethanol, extruding the pulp obtained, transforming the pulp yarns into granules and drying.
• anhydrous solvent such as methylene chloride, or preferably a low molecular weight alkan such as isopropanol, methanol and in particular ethanol
• the mixing can be done in conventional mixers such as planetary, drum or screw mixers for example.
• the wetting of dry powders is carried out until a paste consistency allowing its extrusion is obtained; 2.5 to 3 liters of solvent are used, for example, for a powder load of 5 kg.
• the dough obtained is extruded through multiple dies provided with grids, the pore diameter of which is preferably 0.6 to 1.2 mm. We can for example use an extruder Paudal to carry out this operation.
• the dough strands emerging from the pores of the extruder are broken into micro-cylinders and are advantageously made spherical, especially if it is desired to coat them, for example in a device of the Marumerizer type. ® FujI-Paudal.
• the dried granules can advantageously be coated at this time to protect the active ingredient; the coating must be fine enough not to affect the speed of absorption
• the coating can be carried out using a film-forming agent such as an acrylic derivative, a polyoxyethylene glycol of high molecular weight or, preferably a derivative of cellulose, especially ethyl cellulose.
• the coating coverage represents less than 2% of the total weight of the coated granules, and preferably about 1% of the total weight.
• the cover advantageously also contains one or more plasticizers.
• the plasticizers can be, for example, propylene glycol, diethyl phthalate, dibutyl phthalate, and preferably butyl phthalate; they can also be partial esters of fatty acids and anhydrides of hexitols such as monolaurate or preferably monostearate of sorbitol anhydride.
• the coating is carried out for example in a turbine or in suspension and can be colored if desired.
• the granules can then be distributed in multidose form, or in unit form, in capsules (hard capsules) or cachets.
• the invention thus also relates to a new oral form of clo metacin, characterized in that the granules are distributed by medicinal weight
• the invention also relates to a process for the preparation of a new oral form of clometacin, as defined above, characterized in that 50 to 70% of clometacin, 5 to 20% of '' an alkaline carbonate, and an excipient of anhydrous granulation by wet way, wets progressively using an anhydrous solvent until obtaining a paste, made by extrusion of microcylinders by rupture of the filaments obtained at the exit of the dies , dries them, and, if desired, coats and conditions them in a pharmaceutical form customary for microgranules.
• the microcylinders made substantially spherical and the microspheres obtained are coated.
• the dough obtained is extruded on an extruder Paudal (pore diameter: 0.8 mm); the filaments obtained are broken into microcylinders, made spherical in an apparatus called “Marumerizer R " of the company Paudal, and dried.
• the dry granules are coated with a solution of:
• coated granules are then distributed in capsules dosed with 100.00 mg of clometacin.
• Clometacin is administered orally in the form of tablets, or in the form of capsules containing the conventional granules or the extruded granules.
• Clometacin is measured in the blood after sampling from the femoral vein at the times: 30 min, 1 h, 2 h, 3 h, 4 h, 6 h and 8 h after administration.
• A standard reference tablet (commercial form in France)
• B standard granule
• C extruded granule
• F extruded granule with adjuvant: K 2 CO 3 (29.0 mg) granules according to the invention
• G extruded granule with adjuvant: K 2 CO 3 (29.0 mg) tablet.
• the granules prepared have the following unit formula: - Clometacin ......... .......................... .... 150.00 mg
• the table below indicates the average plasma levels expressed in ⁇ g of clometacin / ml.
• form F extruded granules containing potassium carbonate as an adjuvant
• Table II indicates the average plasma levels expressed in ⁇ g of clometacin / ml.
• the granules have the following unit formula:
• Table III indicates the average plasma levels expressed in ⁇ g of clometacin / ml ( ⁇ ⁇ ) as well as the overall absorption of the active principle in 8 hours, estimated by measuring the areas under the curve (SSC) between 0 and 8 H, expressed in ⁇ g.h.ml -1 .
• the blood concentration peaks (C) of clometacin were also evaluated.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Inorganic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9273377

Family Applications (1)

Country Status (6)

Cited By (5)

Families Citing this family (34)

Citations (4)

Family Cites Families (15)

• 1982
  • 1982-04-26 FR FR8207137A patent/FR2525474A1/fr active Granted
• 1983
  • 1983-04-20 WO PCT/FR1983/000073 patent/WO1983003756A1/fr not_active Ceased
  • 1983-04-22 IT IT48149/83A patent/IT1173705B/it active
  • 1983-04-25 MA MA19998A patent/MA19778A1/fr unknown
  • 1983-04-26 US US06/488,683 patent/US4478819A/en not_active Expired - Fee Related
  • 1983-12-27 OA OA58194A patent/OA07621A/xx unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events